News & Events | Alkermes
Nov 7, 2024 · Sharing stories of patients, employees and communities. View the latest Alkermes news, events and press releases.
Alkermes – A Global Biopharmaceutical Company
Nov 7, 2024 · Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices. View our latest report.
Alkermes Announces FDA Approval of LYBALVI™ for the …
Jun 1, 2021 · Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder. PDF Version. -- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain ---- Commercial Launch Planned for Fourth Quarter 2021 ---- Company to Host Investor Conference Call Today at 8:30 a.m. ET ...
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ...
DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating ...
Investors | Alkermes plc
Sep 26, 2024 · The Investor Relations website contains information about Alkermes plc's business for stockholders, potential investors, and financial analysts.
Alkermes Announces Positive Topline Results From Phase 1b …
DUBLIN, April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily ...
Alkermes Announces Clinical Trial Collaboration and Supply …
DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), Alkermes ...
Leadership, Management Team & Board of Directors | Alkermes
Under the leadership of Richard Pops, CEO, and other seasoned executives, Alkermes has grown to become a publicly traded, global biopharmaceutical company.
Alkermes plc Reports Third Quarter 2022 Financial Results
Nov 2, 2022 · Alkermes plc Reports Third Quarter 2022 Financial Results. PDF Version. — Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio —. — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0.02 —. — Company Announces Intent to Separate Oncology Business —.
Leading a New Era of Patient-Inspired Neuroscience - Alkermes
Alkermes enters 2024 as a standalone, focused neuroscience company poised for continued growth, following a transformational year for our business. With an established commercial portfolio providing real-world insight into conditions facing patients with serious mental illness, and a research pipeline built around our core medicinal chemistry ...